don't get me wrong.. but Sanofi STILL needs to market. why would Mannkind give them sixty five percent if they are not going to market? that's what they were HIRED to do!
Today therapeutic insulin is delivered via injection under the skin (subcutaneous) or via an inhalation device. Therefore, it must be designed (formulated and engineered) in a manner that allows it to be stored externally, taken into the body and reach the bloodstream ready to mimic, as closely as possible, the physiologic action of native insulin.
So if you don't need the $$s now, the best thing to do is sit it out. Don't try to influence/encourage some of the posters (bashers) on this board. If the product is successful (and it will be); pps will take care of itself.
The fact of the matter is Afrezza is going to be hugely successful, and a paradigm shift takes a bit of time.
The reason, we cannot compare to Apple is because unlike a "shiny" new thing you can hold in your hand, Afrezza is a drug, that treats a disease, not a fashion statement. Hence, a lot of Endos, GPs and even
diabetics are taking a wait and see approach, which is understandable.
I challenge anyone to actually post a negative sentiment from one person who has actually used Afrezza and has decided that they want to go back to their injections!!
I am willing to bet most of the shorts are on MARGIN though. Hence the LOONG wait. They do not want to cover yet. Cramer, yes even Jim Cramer, said back in August, shorts will have to cover. Yes the numbers aren't parabolic right now, however, ANYONE who has actually used Afrezza absolutely LOVES it. When this catches fire, (and it's a WHEN) I honestly believe that there will be no stopping the Mannkind locomotive.
I agree PPS will creep up, however, I am having my doubts that it will be orderly. Too much at stake now.
hmmm.. what if.. just what if.. the script numbers spike this Friday?
what if, just what if...EXACTLY 1 year after ADCOM approval, a short has to finally cover their position because they get a margin call? After all, how long can they REALLY sustain paying significant interest?
what if, what if GS's downgrade was a buy signal to their cronies?
what if, what if SNY really does have 1/2 shares slated for a buyout of MNKD that they are allowed to exercise starting Friday?
things that make you go hmmmm
Lets see: 405M share float - 40% owned by Al Mann leaves about 244M shares.
91M/244M is about 38% short.
Cramer back in August 2014 said shorts would eventually have to cover. He said he thinks it is going to be a “Pyrrhic victory” for those betting against Mannkind.
My guess is that these shorts were trapped prior to Adcom, and that was the surprise for everyone.
Let's see Adcom happened when?? Exactly 1 year ago!
So I have a question for more saavy investors.. Any deadlines on how long someone can short?? I assume big player here.
One way investors can do their part! Email your local affiliate to request them to do a story on Inhaled insulin.. and viola! we'll see a lot of this ! I've emailed my affiliate!
The one thing that Cramer said (even though he said it months ago) that is true is "Shorts will have to cover"
This is obviously unsustainable. Question is what is their time frame: a few days, a few months, a year? two years? All I know is I could not afford to pay exorbitant interest rates to those who would loan me shares.
based on his linked in profile. He was marketing Viagra and others..and perhaps EXUBERA???!!
I REALLY wonder if he got canned by Oliver Brandicourt???? and now has a GRIPE??!!!
SHORT NUMBERS AROUND ADCOM
Could it be that Goldman has been the short for a year ? and now it is time to pay the piper?
1. short interest went up almost 7%
2. Adam A (sshloe) Fraudstein does yet another hit piece
3. Meanwhile, anybody that is diabetic and has tried Afrezza loves it! (Unless I'm mistaken, we see the doubting nanies, yet anybody that has actually tried it absolutely LOVES it!)
5. EU, ROW approval forthcoming
6. SNY will do a combined marketing effort for their DIABETES PORTFOLIO -- Toujeo and Afrezza, the one two knock out punch - BASIL and BOLUS !!
See for yourself:
Our principal medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide (2).
Apidra® (insulin glulisine) a rapid-acting human insulin analog (2).
Insuman®, a range of rapid- and intermediate-acting human insulins (2).
Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist (2).
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic (2).
Afrezza® (insulin human) is a rapid-acting, inhaled insulin. Only available in the United-States.